Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Apr 30, 2023 12:21pm
122 Views
Post# 35421640

BMI isn't the issue central obesity is...

BMI isn't the issue central obesity is...

 

"But growing appreciation of the limitations of BMI is causing many clinicians to consider alternative measures of obesity that can better assess both the amount of adiposity as well as its body location, an important determinant of the cardiometabolic consequences of fat.

 

The 2022 NICE review also said that it is "important to estimate central adiposity when assessing future health risks, including for people whose BMI is in the healthy weight category."

Alternative metrics include waist circumference and/or waist-to-height ratio (WHtR); imaging methods such as computed tomography (CT), magnetic resonance imaging (MRI), and dual-energy X-ray absorptiometry (DEXA); and bioelectrical impedance to assess fat volume and location. All have made some inroads on the tight grip BMI has had on obesity assessment.

 

Unfortunately, BMI is an imperfect measure of body composition that differs with ethnicity, sex, body frame, and muscle mass," note Laine and Wee."

 

It really shows the importance of education of unaware or clinically detached physicians and also their patients (in order to directly raise the awareness) because many primary care providers and their patients are not aware of the constantly evolving medical findings resulting in misdiagnosis and incorrect/insufficient treatment. Obese or not the medical complications cause by excessive fat, what matters most is where mostly the the fat is stored. Central obesity which is the the cause of many metabolic diseases can not be measured by total weight to height ratio but the measurement of the waist to height ratio. The idea is to find the fat responsible for causing issues for vital organs followed by serious conditions among others cardiovascular diseases, stroke, diabetes, high blood pressure and of course fatty liver. 

https://www.medscape.com/viewarticle/991210

<< Previous
Bullboard Posts
Next >>